HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea · Delayed Price · Currency is KRW 17,420
+490 (2.89%)
Apr 10, 2026, 3:30 PM KST
HLB Pharmaceutical Revenue
In the year 2025, HLB Pharmaceutical had annual revenue of 205.58B KRW with 49.97% growth. HLB Pharmaceutical had revenue of 63.42B in the quarter ending December 31, 2025, with 91.67% growth.
Revenue
205.58B
Revenue Growth
+469.48%
P/S Ratio
1.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
244.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 205.58B | 68.50B | 49.97% |
| Dec 31, 2024 | 137.08B | 100.98B | 279.73% |
| Dec 31, 2019 | 36.10B | 15.56B | 75.75% |
| Dec 31, 2018 | 20.54B | 4.98B | 32.03% |
| Dec 31, 2017 | 15.56B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JW Holdings | 969.57B |
| Chong Kun Dang Holdings | 959.01B |
| Suheung | 722.31B |
| Daewon Pharmaceutical | 605.43B |
| Samjin Pharmaceuticals | 274.03B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| Samil Pharmaceutical Co.,Ltd | 210.25B |
| Boditech Med | 162.09B |